[go: up one dir, main page]

PE20091961A1 - Nuevos derivados azabiciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados azabiciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
PE20091961A1
PE20091961A1 PE2009000758A PE2009000758A PE20091961A1 PE 20091961 A1 PE20091961 A1 PE 20091961A1 PE 2009000758 A PE2009000758 A PE 2009000758A PE 2009000758 A PE2009000758 A PE 2009000758A PE 20091961 A1 PE20091961 A1 PE 20091961A1
Authority
PE
Peru
Prior art keywords
azabycle
propoxi
preparation procedure
hex
derivatives
Prior art date
Application number
PE2009000758A
Other languages
English (en)
Inventor
Patrick Casara
Alain Dhainaut
Fany Panayi
Anne-Marie Chollet
Pierre Lestage
Anita Roger
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20091961A1 publication Critical patent/PE20091961A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN DERIVADO AZABICICLICO DE FORMULA (I), DONDE ALK ES UN ALQUILENO C2-C6 LINEAL O RAMIFICADO; W ES UN GRUPO -NR'-C(=O)-R O -C(=O)-NR'-R; R Y R' SON H O UN GRUPO ALQUILO C1-C6 LINEAL O RAMIFICADO OPCIONALMENTE SUSTITUIDO CON HALOGENO, OH O ALCOXI C1-C6. SON COMPUESTOS PREFERIDOS: N-(4-{3-[(1R,5S)-3-AZABICICLO[3.1.0]HEX-3-IL]PROPOXI}FENIL)-N-METILACETAMIDA, 4-{3-[(1R,5S)-3-AZABICICLO[3.1.0]HEX-3-IL]PROPOXI}BENZAMIDA, N-(4-{3-[(1R,5S)-3-AZABICICLO[3.1.0]HEX-3-IL]PROPOXI}FENIL)-2-METOXIACETAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INTERACTUAN CON LOS SISTEMAS HISTAMINERGICOS CENTRALES Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS COGNITIVOS Y PSICOCOMPORTAMENTALES ASOCIADOS CON EL ENVEJECIMIENTO CEREBRAL O ENFERMEDADES TALES COMO ALZHEIMER, PARKINSON, ENFERMEDAD DE PICK, ENTRE OTRAS
PE2009000758A 2008-06-13 2009-06-01 Nuevos derivados azabiciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen PE20091961A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0803297A FR2932479A1 (fr) 2008-06-13 2008-06-13 Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
PE20091961A1 true PE20091961A1 (es) 2010-01-23

Family

ID=40227963

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000758A PE20091961A1 (es) 2008-06-13 2009-06-01 Nuevos derivados azabiciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Country Status (29)

Country Link
US (1) US7906547B2 (es)
EP (1) EP2133333A1 (es)
JP (1) JP2009298790A (es)
KR (1) KR20090129958A (es)
CN (1) CN101602706A (es)
AP (1) AP2009004891A0 (es)
AR (1) AR072101A1 (es)
AU (1) AU2009202341A1 (es)
BR (1) BRPI0902395A2 (es)
CA (1) CA2668527A1 (es)
CL (1) CL2009001377A1 (es)
CO (1) CO6190096A1 (es)
CR (1) CR10844A (es)
EA (1) EA200900692A1 (es)
EC (1) ECSP099396A (es)
FR (1) FR2932479A1 (es)
GT (1) GT200900150A (es)
MA (1) MA31141B1 (es)
MX (1) MX2009005891A (es)
MY (1) MY144748A (es)
NI (1) NI200900114A (es)
NZ (1) NZ577438A (es)
PE (1) PE20091961A1 (es)
SG (1) SG158015A1 (es)
SV (1) SV2009003292A (es)
TW (1) TW201000101A (es)
UY (1) UY31857A1 (es)
WO (1) WO2009150331A1 (es)
ZA (1) ZA200903939B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10892398B2 (en) * 2019-03-28 2021-01-12 Johannes Pollanen Qubit hardware for electrons on helium
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515013B2 (en) * 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
US7232835B2 (en) * 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
CN101189228A (zh) * 2005-04-08 2008-05-28 辉瑞产品有限公司 用作i型甘氨酸转运抑制剂的二环[3.1.0]杂芳酰胺
EP1842846A1 (en) * 2006-04-07 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Phenylpiperidine derivatives as melanocortin-4 receptor modulators
AU2007274598A1 (en) * 2006-07-21 2008-01-24 Lupin Limited Antidiabetic azabicyclo [3. 1. 0] hexan compounds

Also Published As

Publication number Publication date
ECSP099396A (es) 2010-01-29
UY31857A1 (es) 2009-08-31
GT200900150A (es) 2011-08-25
NI200900114A (es) 2010-02-03
NZ577438A (en) 2010-09-30
MX2009005891A (es) 2010-02-17
AU2009202341A1 (en) 2010-01-07
CR10844A (es) 2009-07-23
ZA200903939B (en) 2010-04-28
KR20090129958A (ko) 2009-12-17
CN101602706A (zh) 2009-12-16
WO2009150331A1 (fr) 2009-12-17
SG158015A1 (en) 2010-01-29
TW201000101A (en) 2010-01-01
CA2668527A1 (fr) 2009-12-13
EP2133333A1 (fr) 2009-12-16
EA200900692A1 (ru) 2009-12-30
AR072101A1 (es) 2010-08-04
US20090312389A1 (en) 2009-12-17
JP2009298790A (ja) 2009-12-24
MA31141B1 (fr) 2010-02-01
MY144748A (en) 2011-10-31
BRPI0902395A2 (pt) 2010-04-20
SV2009003292A (es) 2010-02-01
US7906547B2 (en) 2011-03-15
CL2009001377A1 (es) 2010-05-28
AP2009004891A0 (en) 2009-06-30
CO6190096A1 (es) 2010-08-19
FR2932479A1 (fr) 2009-12-18

Similar Documents

Publication Publication Date Title
UY32967A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina
ECSP11010754A (es) Derivados de triazol útiles para el tratamiento de enfermedades
CR20130307A (es) Composiciones y métodos para modular el fxr
MX2022004467A (es) Procedimiento para preparar (4s)-4-(4-ciano-2-metoxi-fenil)-5-etox i-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxilato de 2-cianoetilo mediante separacion de racematos utilizando esteres diastereomericos de acido tartarico.
MX374409B (es) Derivados de etinilo como moduladores del receptor de glutamato metabotrópico.
ECSP10010209A (es) Agonistas novedosos de los receptores de glucocorticoides
CO6311106A2 (es) Derivados novedosos del acido oleanólico con saturacion del anillo c
CR11627A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores c-met
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
UY32077A (es) Inhibidores de quinasa tipo polo
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CO6351778A2 (es) Acidos naftilaceticos
CU20150058A7 (es) Derivados de imidazopiridazina como receptores de moduladores gabaa
ECSP11011160A (es) Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio
PE20171257A1 (es) Analogos de urea unidos sustituidos como moduladores de sirtuina
AR093042A1 (es) Derivados de etinilo
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
AR074467A1 (es) Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
PE20091961A1 (es) Nuevos derivados azabiciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6321246A2 (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
AR085428A1 (es) (3r,4r)-4-ciano-3,4-difenilbutanoatos sustituidos, procedimiento para su preparacion y su uso como herbicidas y reguladores de crecimiento de plantas
CR20120274A (es) Procedimiento de sístesis y forma cristalina del hidrocloruro de 4-{3[cis-hexahidrociclopenta[c]pirrol-2-(1h)-il]propoxi} benzamida así como las composiciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
FD Application declared void or lapsed